Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016
Go back to Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 57.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $57.22 | 52 Week High | $17.00 | |||
| Open | $57.22 | 52 Week Low | $3.55 | |||
| Day High | $57.22 | P/E | N/A | |||
| Day Low | $57.22 | EPS | $-1.33 | |||
| Volume | 15,786 | |||||
